API
< Back to all clusters
[HEALTH] · Germany · 2 sources

started · updated

XBiotech reports positive Phase II TASKIN results for mCRC

XBiotech has announced final results from the randomized Phase II TASKIN study, which evaluated the efficacy of the monoclonal antibody Vilamakitug in treating refractory metastatic colorectal cancer (mCRC). The study met its primary efficacy endpoint based on a two-stage Simon design.

At the 12-month mark, 61.3% of evaluable patients in the Vilamakitug arm were alive, compared to 55.7% in the control group receiving placebo plus standard chemotherapy. While the overall difference in median progression-free survival did not reach statistical significance, an exploratory analysis showed significant benefits in a specific subgroup. Patients with right-sided (proximal) tumors saw a 62% reduction in the risk of death within 12 months. Researchers suggest this efficacy may be linked to increased IL-1α expression in these specific tumors.

The treatment was reported to be well-tolerated, with only 1.3% of patients discontinuing administration due to adverse effects.

Entities

François Ghiringhelli · INCA · TASKIN study · Vilamakitug · XBiotech

Sources